Raymond James Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
I'm PortAI, I can summarize articles.
According to TipRanks, Nachman is a 2-star analyst with an average return of 0.7% and a 46.35% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, AbbVie, and Pacira Pharmaceuticals. Currently, the analyst consensus on Ionis Pharmaceuticals is a Strong Buy with an average price target of $76.55, representing a 9.42% upside. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $80.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments